Antitumor immune response induced by i.t. injection of vector-activated dendritic cells and chemotherapy suppresses metastatic breast cancer
/in Breast Cancer, International Publications /von 2006-08-01 / Mol. Cancer Ther. 2006 Aug;5(8):1975-85Newcastle disease virus exerts oncolysis by both intrinsic and extrinsic caspase-dependent pathways of cell death
/in International Publications, Newcastle Disease Virus /von 2006-08-01 / J. Virol. 2006 Aug;80(15):7522-34Immunotherapy for prostate cancer: what’s the future?
/in International Publications, Prostate Cancer /von 2006-08-01 / Hematol. Oncol. Clin. North Am. 2006 Aug;20(4):965-83, xiTargeting the heat shock factor 1 by RNA interference: a potent tool to enhance hyperthermochemotherapy efficacy in cervical cancer
/in Cervical Cancer, International Publications /von 2006-08-01 / Cancer Res. 2006 Aug;66(15):7678-85
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum
- Individualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution